Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.
about
A Temporal Model of Human IgE and IgG Antibody FunctionIgG4-related disease: current challenges and future prospectsImmunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesComplement and its role in protection and pathogenesis of flavivirus infectionsComplement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile VirusImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesThe Complement System and Antibody-Mediated Transplant RejectionIgE-based immunotherapy of cancer: challenges and chances.De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease.Immunogenicity to biologics: mechanisms, prediction and reduction.IgG subclasses and allotypes: from structure to effector functions.Human leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies.Immunology of IgG4-related disease.HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor.Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.Genetically-engineered antibodies: tools for the study of diverse properties of the antibody molecule.Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens.Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.Novel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice.CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaquesNovel IgG-Degrading Enzymes of the IgdE Protease Family Link Substrate Specificity to Host Tropism of Streptococcus SpeciesStructural features of human immunoglobulin G that determine isotype-specific differences in complement activation.Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cellsComplement component 3 binding to Haemophilus influenzae type b in the presence of anticapsular and anti-outer membrane antibodies.Antibody-dependent alternate pathway of complement activation in opsonophagocytosis of Porphyromonas gingivalis.Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complementImmunoglobulin subclass profiles of anti-idiotypic antibodies to GAD65Ab differ between type 1 diabetes patients and healthy individuals.Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.Passive acquisition of anti-Staphylococcus aureus antibodies by newborns via transplacental transfer and breastfeeding, regardless of maternal colonization.Cardiac antibody-mediated rejection.IgG4-associated cholangitis: a comprehensive review.The dual nature of interleukin-10 in pemphigus vulgaris.Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.Comparative analysis of the antibody response to the HTLV-I gag and env proteins in HTLV-I asymptomatic carriers and HAM/TSP patients: an isotype and subclass analysis.Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.B Cell Responses Associated with Vaccine-Induced Delayed SIVmac251 Acquisition in Female Rhesus Macaques.Discriminating complement-mediated acute transfusion reaction for type O+ red blood cells transfused into a B+ recipient with the complement hemolysis using human erythrocytes (CHUHE) assay.Human immunoglobulin classes and subclasses show variability in VDJ gene mutation levels.
P2860
Q21131207-CF0390C5-1E92-496E-972D-F25B373CC1A8Q26765309-299C8C7B-429C-43B6-A7C9-560F8E38352AQ26766424-3F4BA3E4-5508-40C6-9492-6239684F0B4FQ27490236-FB181CB3-0D61-4A7C-A303-7AFA02C265B7Q27490423-D1FEA613-2551-4AB6-88BC-B3A111AC9370Q28069362-C82F316B-2A2F-478A-8E79-9B42760822FBQ28087773-816AE49E-330C-4230-8257-E80598A6A2A5Q33619979-258C9087-56A6-4F3A-B9FD-AD0BA99F8C91Q34112037-82939E63-C20D-41EB-A5AB-9F987AB09032Q34296526-4C39F5E6-6B95-4280-8FE1-B00FE298B064Q34368678-3168109C-AAD5-4680-B902-C3890ED03CC5Q34451956-5DAD1824-A200-4C32-A4A2-8618F265FF67Q34471314-3D9F3CF6-9AB8-4DB7-A34A-30D72D93FCA2Q34623592-3F54F5AF-BE1E-4E1A-9B94-2C448A58E53FQ34700533-D5908FDB-D02B-46C5-B4F7-DE22E9A2CFA0Q34979203-A59C2433-1596-4665-9960-3DF331F061C9Q35180033-E043A88E-DD2B-4E10-8F0D-B77336FFF996Q35422370-894B9C61-86C9-4BE5-8401-4558AD8AA42CQ35531167-D142FBEA-4269-4056-8890-21D4CC7CFDB0Q35665351-68D5D8A1-A688-4201-AF01-D0E5AD185832Q35693333-3654AC0B-5B50-4D8E-80DE-F02BE6943D9CQ36165324-9B68C0D4-CC7B-4FDE-BAC3-D2C9B460EFB4Q36362075-02B85352-18C0-4DDA-A067-714303465949Q36363690-2E68DF6C-35F5-4D6A-A330-11C4114F69DAQ36392832-123070ED-1180-4AB9-B8CC-05B1DF4E4D8BQ36953462-A72EA5AD-9EB1-4D11-8D87-6FE1FEB74E57Q36965172-6EDEAE4B-EB61-4C6C-B7ED-B2A85C4AB20CQ37051617-65CE346C-0B6B-4083-943D-D85C1D5D55E6Q37373912-2C5E5842-5B77-4CC8-8AE5-DF08C9DE64B1Q37452067-CB63A0BD-F738-4713-B5F4-9F4A7471CCEDQ37522821-E3635BC2-4CD1-4A1D-89A9-33D0932ACE22Q38002449-627C4934-F9C2-4116-81B9-5963B5F1FF08Q38222686-9736B020-8DB5-45BA-9EB0-3646B2D8C3FEQ38281273-79025F2D-69CA-4E5F-856D-64E72454A622Q38827908-CED59104-4CE7-4E3A-8AFE-19552170A0DDQ38968727-52D003D1-27AF-4EC9-B0DF-C8F9018DA60DQ39452477-95822227-ED36-4156-88C7-D303CE065E16Q39481098-C7A7F338-C1E1-4A82-8D4D-22699FBB7109Q40113202-18E28F76-7620-4195-8DD2-CCFF8170D841Q40199265-FAE43C18-6D86-4152-BD1F-369DC961085B
P2860
Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Human monoclonal IgG isotypes ...... he level of C4 as well as C1q.
@en
Human monoclonal IgG isotypes ...... he level of C4 as well as C1q.
@nl
type
label
Human monoclonal IgG isotypes ...... he level of C4 as well as C1q.
@en
Human monoclonal IgG isotypes ...... he level of C4 as well as C1q.
@nl
prefLabel
Human monoclonal IgG isotypes ...... he level of C4 as well as C1q.
@en
Human monoclonal IgG isotypes ...... he level of C4 as well as C1q.
@nl
P2093
P2860
P356
P1476
Human monoclonal IgG isotypes ...... he level of C4 as well as C1q.
@en
P2093
P2860
P304
P356
10.1084/JEM.168.1.127
P407
P577
1988-07-01T00:00:00Z